tradingkey.logo

CytomX Therapeutics Inc <CTMX.OQ> expected to post earnings of 12 cents a share - Earnings Preview

ReutersMay 2, 2025 8:33 PM
  • CytomX Therapeutics Inc CTMX.OQ CTMX.O is expected to show a fall in quarterly revenue when it reports results on May 6 (estimated) for the period ending March 31 2025

  • The South San Francisco California-based company is expected to report a 25.6% decrease in revenue to $30.839 million from $41.46 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for CytomX Therapeutics Inc is for earnings of 12 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for CytomX Therapeutics Inc is $4.25​, above​ its last closing price of $0.76. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.15

-0.20

0.23

Beat

217.5

Sep. 30 2024

-0.16

-0.17

0.07

Beat

140.7

Jun. 30 2024

-0.12

-0.14

-0.08

Beat

44.2​

Mar. 31 2024

-0.08

-0.08

0.17

Beat

305.2

​​Dec. 31 2023

0.01

-0.03

0.01

Beat

135

Sep. 30 2023

-0.15

-0.19

0.04

Beat

121.2​

Jun. 30 2023

-0.18

-0.20

-0.02

Beat

90.2

Mar. 31 2023

-0.12

-0.11

-0.05

Beat

52.7

This summary was machine generated May 2 at 20:33 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI